Virginia Kaklamani

15.5k total citations
176 papers, 5.2k citations indexed

About

Virginia Kaklamani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Virginia Kaklamani has authored 176 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 54 papers in Cancer Research. Recurrent topics in Virginia Kaklamani's work include Cancer Treatment and Pharmacology (56 papers), Advanced Breast Cancer Therapies (50 papers) and HER2/EGFR in Cancer Research (38 papers). Virginia Kaklamani is often cited by papers focused on Cancer Treatment and Pharmacology (56 papers), Advanced Breast Cancer Therapies (50 papers) and HER2/EGFR in Cancer Research (38 papers). Virginia Kaklamani collaborates with scholars based in United States, Italy and Spain. Virginia Kaklamani's co-authors include Christos S. Mantzoros, William J. Gradishar, Boris Pasche, Jeffrey S. Flier, Carlos L. Arteaga, Evangelia Kaklamani, Ariella B. Hanker, Phaedon Kaklamanis, Athena Linos and Christos S. Mantzoros and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Nature Communications.

In The Last Decade

Virginia Kaklamani

166 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Virginia Kaklamani United States 42 2.1k 1.6k 958 943 854 176 5.2k
Charlotte E. Ariyan United States 31 2.0k 0.9× 2.0k 1.2× 342 0.4× 366 0.4× 1.4k 1.6× 100 6.1k
Shigeki Nakagawa Japan 38 1.8k 0.9× 1.7k 1.0× 994 1.0× 846 0.9× 664 0.8× 184 4.9k
Tanya B. Dorff United States 36 1.6k 0.7× 1.4k 0.9× 820 0.9× 1.9k 2.0× 275 0.3× 288 5.2k
Linda Vona‐Davis United States 29 1.4k 0.6× 911 0.6× 835 0.9× 218 0.2× 779 0.9× 65 3.1k
Cullen M. Taniguchi United States 25 939 0.4× 2.8k 1.7× 962 1.0× 577 0.6× 1.2k 1.4× 128 5.9k
David‐Alexandre Trégouët France 45 948 0.4× 1.9k 1.2× 675 0.7× 1.2k 1.2× 818 1.0× 189 6.8k
Christos Markopoulos Greece 33 2.5k 1.2× 1.0k 0.6× 1.7k 1.7× 615 0.7× 491 0.6× 198 4.7k
Alessio Nencioni Italy 42 1.4k 0.6× 2.2k 1.3× 661 0.7× 228 0.2× 985 1.2× 168 5.6k
Olaf Ortmann Germany 41 1.7k 0.8× 1.6k 1.0× 925 1.0× 451 0.5× 420 0.5× 346 6.3k
Amanda I. Phipps United States 36 2.6k 1.2× 802 0.5× 1.1k 1.2× 683 0.7× 334 0.4× 141 4.3k

Countries citing papers authored by Virginia Kaklamani

Since Specialization
Citations

This map shows the geographic impact of Virginia Kaklamani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia Kaklamani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia Kaklamani more than expected).

Fields of papers citing papers by Virginia Kaklamani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia Kaklamani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia Kaklamani. The network helps show where Virginia Kaklamani may publish in the future.

Co-authorship network of co-authors of Virginia Kaklamani

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia Kaklamani. A scholar is included among the top collaborators of Virginia Kaklamani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia Kaklamani. Virginia Kaklamani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Adeyelu, Tolulope, Andrew Elliott, Phillip L. Walker, et al.. (2024). Genomic and transcriptomic landscape of HER2-low breast cancer. Breast Cancer Research and Treatment. 209(2). 323–330. 4 indexed citations
2.
Bardia, Aditya, Javier Cortés, François‐Clément Bidard, et al.. (2024). Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical Cancer Research. 30(19). 4299–4309. 33 indexed citations
3.
Kelly, William, Virginia Kaklamani, Kate Lathrop, et al.. (2024). Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nature Communications. 15(1). 6707–6707. 12 indexed citations
4.
Venkata, Prabhakar Pitta, Santosh Timilsina, Deepika Singh, et al.. (2023). Abstract P3-07-19: Anti-depressant Amitriptyline Augments the Efficacy of Tamoxifen in ER positive breast cancer. Cancer Research. 83(5_Supplement). P3–7. 1 indexed citations
5.
6.
Bustos, Matías A., Estelamari Rodríguez, Sarah Sammons, et al.. (2023). Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer. Cancer Research. 83(5_Supplement). HER2–12. 2 indexed citations
7.
Graff, Stephanie L., Andrew Elliott, Estelamari Rodríguez, et al.. (2023). 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer. ESMO Open. 8(1). 101404–101404. 3 indexed citations
8.
Sparano, Joseph A., Robert J. Gray, Della Makower, et al.. (2023). Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates. Cancer Research. 83(5_Supplement). GS1–5. 4 indexed citations
9.
Kelly, William, Andrea Gilbert, Joel Michalek, et al.. (2023). CTNI-10. SACITUZUMAB GOVITECAN FOR BREAST CANCER BRAIN METASTASIS. Neuro-Oncology. 25(Supplement_5). v75–v75. 1 indexed citations
10.
Tolaney, Sara M., Kevin Kalinsky, Virginia Kaklamani, et al.. (2021). Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clinical Cancer Research. 27(11). 3061–3068. 90 indexed citations
11.
Bardia, Aditya, Virginia Kaklamani, Sharon Wilks, et al.. (2021). Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of Clinical Oncology. 39(12). 1360–1370. 67 indexed citations
12.
Kaklamani, Virginia, et al.. (2021). Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer Risk. Current Treatment Options in Oncology. 22(10). 85–85. 4 indexed citations
13.
Brenner, Andrew, Renu Pandey, Virginia Kaklamani, et al.. (2020). 373MO Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours. Annals of Oncology. 31. S401–S401. 11 indexed citations
14.
Chen, Guang, Hakim Bouamar, Bingzhi Wang, et al.. (2019). Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression. Clinical Cancer Research. 26(6). 1486–1496. 19 indexed citations
15.
Telli, Melinda L., Charles C. Chu, Sunil Badve, et al.. (2019). Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research. 26(11). 2704–2710. 23 indexed citations
16.
17.
Hanker, Ariella B., Virginia Kaklamani, & Carlos L. Arteaga. (2019). Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discovery. 9(4). 482–491. 172 indexed citations
18.
Wu, Yanming, Zhao Zhang, Cecilia J. Proietti, et al.. (2017). Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis. Cancer Research. 78(3). 671–684. 80 indexed citations
19.
Rahman, Tahir, et al.. (2016). Manic and nonadherent, with a diagnosis of breast cancer. Current psychiatry. 15(1). 51–57.
20.
Kaklamani, Virginia, et al.. (2010). Lapatinib and breast cancer: current indications and outlook for the future. Expert Review of Anticancer Therapy. 10(8). 1171–1182. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte E. Ariyan Breakdown of academic impact, for papers by Shigeki Nakagawa Breakdown of academic impact, for papers by Tanya B. Dorff Breakdown of academic impact, for papers by Linda Vona‐Davis Breakdown of academic impact, for papers by Cullen M. Taniguchi Breakdown of academic impact, for papers by David‐Alexandre Trégouët Breakdown of academic impact, for papers by Christos Markopoulos Breakdown of academic impact, for papers by Alessio Nencioni Breakdown of academic impact, for papers by Olaf Ortmann Breakdown of academic impact, for papers by Amanda I. Phipps
Rankless by CCL
2026